U.S. stock market midday update: Shuttle Pharmaceuticals up 153%! Clear capital flow, market sentiment triggers volatility attention

U.S. Stock Market Midday Update Shuttle Pharmaceuticals, up 153.01%, with a year-to-date increase of 127.47%, has no significant recent news. Trading is active, with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks Ranking High in Industry Trading Volume RAPT Therapeutics up 63.96%. Based on recent news, On January 20, British pharmaceutical giant GlaxoSmithKline announced it would acquire RAPT Therapeutics for $2.2 billion. The deal includes a cash purchase price of $58 per share, representing a significant premium over RAPT's last closing price. This news drove RAPT's stock price up nearly 64% in pre-market trading. On January 20, RAPT Therapeutics' stock price reached $57.40 in pre-market trading, setting a new 52-week high. This acquisition will give GlaxoSmithKline global rights to RAPT's food allergy drug ozureprubart (excluding mainland China, Macau, Taiwan, and Hong Kong). On January 20, GlaxoSmithKline's Chief Scientific Officer Tony Wood stated that the addition of ozureprubart would bring a highly promising new therapy to GSK's R&D pipeline, expected to be administered every 12 weeks, providing lasting protection for patients. M&A activity in the pharmaceutical industry is increasing, with market expectations for transaction volume and total value to rise by 2026. ImmunityBio up 19.84%. Based on recent key news: On January 20, ImmunityBio announced that enrollment in its registration trial for BCG-naïve non-muscle invasive bladder cancer exceeded expectations, driving the stock price up. The company stated that long-term data shows nearly all patients treated with Anktiva survived for three years, and over 80% of patients retained their bladders, avoiding surgery. This news boosted market confidence, with the stock price rising 39.8%. Source: Benzinga On January 20, the FDA suggested that ImmunityBio submit additional data to support the resubmission of its sBLA, with no new clinical trials expected. The company plans to resubmit the application within 30 days, stabilizing investor sentiment. Source: Benzinga On January 20, analysts maintained ImmunityBio's target price at $24 per share, reflecting market confidence in its future growth. Source: Benzinga The biotechnology industry has recently performed strongly, with significant capital inflows. Corvus Pharmaceuticals up 78.14%. Based on recent key news: On January 20, Corvus Pharmaceuticals announced positive results from its randomized, double-blind, placebo-controlled Phase 1 clinical trial of soquelitinib in patients with moderate to severe atopic dermatitis 75% of patients achieved EASI 75, 25% achieved EASI 90, and 33% achieved IGA 0/1, demonstrating good safety and efficacy, which drove the stock price up. Source: Reuters On January 20, Corvus Pharmaceuticals plans to initiate a Phase 2 trial of soquelitinib in the first quarter of 2026, further enhancing market confidence in its products and promoting stock price increases. Source: Reuters On January 20, Corvus Pharmaceuticals detailed the results of its Phase 1 trial during a conference call and live webcast, increasing investor confidence in the company's future development, leading to a rise in stock price. Source: Public Technologies The biopharmaceutical industry has recently performed strongly, with significant capital inflows. Stocks ranked among the top in industry market capitalization AbbVie fell 1.75%. Based on recent key news: On January 17, AbbVie and Genmab announced the topline results of the EPCORE® DLBCL-1 trial. The trial results showed positive efficacy, and AbbVie plans to discuss next steps with global regulatory agencies. This news caused stock price fluctuations. On January 19, market analysts rated AbbVie as "Moderate Buy," but it was not included in the recommended list. Analysts believe that five other stocks are more attractive, which may affect investor confidence. On January 17, AbbVie increased its advertising spending on pharmaceuticals in the U.S. and Japanese markets, indicating the company's proactive strategy in market promotion, which may impact stock prices. The biopharmaceutical industry faces regulatory challenges